ITEM 2.02 Results of Operations and Financial Condition
On
ITEM 7.01 Regulation FD Disclosure
On its earnings conference call for the three and six months ended
FORWARD-LOOKING STATEMENTS
Exhibits 99.1 and 99.2 contain "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995, including statements
relating to our business, goals, strategy and financial and operational
outlook. These "forward-looking statements" are management's present
expectations of future events and are subject to a number of risks and
uncertainties that could cause actual results to differ materially and adversely
from those set forth in or implied by forward-looking statements. These risks
include, but are not limited to: the risk that sales and profit margins of our
existing molecular diagnostic tests and pharmaceutical and clinical services may
decline or will not continue to increase at historical rates; risks related to
our ability to transition from our existing product portfolio to our new tests;
risks related to changes in the governmental or private insurers reimbursement
levels for our tests or our ability to obtain reimbursement for our new tests at
comparable levels to our existing tests; risks related to increased competition
and the development of new competing tests and services; the risk that we may be
unable to develop or achieve commercial success for additional molecular
diagnostic tests and pharmaceutical and clinical services in a timely manner, or
at all; the risk that we may not successfully develop new markets for our
molecular diagnostic tests and pharmaceutical and clinical services, including
our ability to successfully generate revenue outside
--------------------------------------------------------------------------------
our ability to successfully integrate and derive benefits from any technologies
or businesses that we license or acquire; risks related to our projections about
the potential market opportunity for our products; the risk that we or our
licensors may be unable to protect or that third parties will infringe the
proprietary technologies underlying our tests; the risk of patent-infringement
claims or challenges to the validity of our patents; risks related to changes in
intellectual property laws covering our molecular diagnostic tests and
pharmaceutical and clinical services and patents or enforcement in
--------------------------------------------------------------------------------
ITEM 9.01 Financial Statements and Exhibits.
Exhibit Number Description 99.1 Earnings release datedFebruary 6, 2020 for the three and six months endedDecember 31, 2019 , as corrected onFebruary 7, 2020 . 99.2* Earnings call slide presentation datedFebruary 6, 2020 for the three and six months endedDecember 31, 2019 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). *Previously filed.
The exhibit(s) may contain hypertext links to information on our website or other parties' websites. The information on our website and other parties' websites is not incorporated by reference into this Current Report on Form 8-K and does not constitute a part of this Form 8-K.
In accordance with General Instruction B-2 of Form 8-K, the information set forth in Item 2.02 and Item 7.01 and in Exhibits 99.1 and 99.2 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
--------------------------------------------------------------------------------
© Edgar Online, source